BONVIVA 100mg tablets drug use results surveillance

BONVIVA 100mg tablets drug use results surveillance - BONVIVA 100mg tablets drug use results surveillance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023992

Enrollment

1500

Registered

2016-09-12

Start date

2016-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have no previous treatment with BONVIVA 100mg tablets for osteoporosis

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Safety 1.Adverse drug reaction status/incidence 2.Identification and confirmation of factors which affect safetyprofiles	—

Secondary

Measure	Time frame
Efficacy 1.Percent change from baseline in bone mineral density (BMD) 2.Percent change from baseline in bone turnover markers 3.Incidence of new fracture (including exacerbation of fracture)	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co. Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results